Equities Analysts Issue Forecasts for EVAX FY2029 Earnings

Evaxion Biotech A/S (NASDAQ:EVAX) – Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Evaxion Biotech A/S in a research report issued on Monday, February 3rd. HC Wainwright analyst S. Ramakanth expects that the company will earn $0.11 per share for the year. HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Evaxion Biotech A/S’s current full-year earnings is ($0.43) per share.

Separately, Lake Street Capital dropped their price target on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday.

Evaxion Biotech A/S Stock Performance

Shares of EVAX stock opened at $3.27 on Tuesday. The company’s 50-day moving average is $4.79 and its 200 day moving average is $10.58. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00. The company has a market capitalization of $3.83 million, a price-to-earnings ratio of -2.26 and a beta of -0.28. Evaxion Biotech A/S has a one year low of $2.22 and a one year high of $23.70.

Institutional Trading of Evaxion Biotech A/S

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Catalina Capital Group LLC purchased a new stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned about 2.98% of Evaxion Biotech A/S as of its most recent SEC filing. 11.04% of the stock is currently owned by institutional investors and hedge funds.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.